IRWD

Ironwood Pharmaceuticals is a commercial-stage biopharmaceutical company focused on gastrointestinal (GI) diseases. The company's lead product, LINZESS, is a leading prescription medication for adults suffering from irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Ironwood has built its business around developing and commercializing innovative therapies for GI disorders that significantly impact patients' quality of life. The company collaborates with partners to maximize the reach of its products globally. Ironwood continues to invest in research and development for additional GI and metabolic disorder treatments.